Beijing Erai Therapeutics has identified aminoheteroaryl compounds acting as mitochondrial brown fat uncoupling protein 1 (UCP1) activators reported to be useful for the treatment of nonalcoholic steatohepatitis (NASH), diabetes and obesity.

The FDA has approved Eccogene's IND application to commence a phase I trial of the company's thyroid hormone receptor (THR) agonist ECC-4703 in the U.S.

Cambridge Enterprise and European Molecular Biology Laboratory have presented new peptides derived from full-length factor V (FV) protein acting as T-cell activation inhibitors reported to be useful for the treatment of inflammatory bowel disease, type 1 diabetes, systemic lupus erythematosus, psoriasis, vasculitis, idiopathic pulmonary fibrosis, vitiligo and lupus nephritis, among other disorders.

According to a new study published in the July 27, 2022, issue of Science Translational Medicine, a lower intake of fermentable carbohydrates produces changes in the intestinal microbiota that decrease histamine production reducing chronic abdominal pain in patients with irritable bowel syndrome (IBS).